Document is current
Any future updates will be listed below
-
Authors
Albrecht, Katinka https://orcid.org/0000-0003-0886-0294
Troll, Wiebke
Callhoff, Johanna https://orcid.org/0000-0002-3923-2728
Strangfeld, Anja https://orcid.org/0000-0002-6233-022X
Ohrndorf, Sarah https://orcid.org/0000-0001-5943-4688
Mucke, Johanna https://orcid.org/0000-0001-8915-7837
-
Funding
Funding for this research was provided by:
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 3 June 2025
First Online: 27 June 2025
Declarations
:
: KA declares no competing interests. WT has received speaker honoraria from GSK, consultant fees from GSK, Roche and Pfizer. JM has received consultant fees from AbbVie, AstraZeneca, BMS, GlaxoSmithKline, Novartis, Lilly, UCB, Ostuka; Speakers fees from AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Janssen-Cilag, Lilly, Novartis, Otsuka, grants/research support from GlaxoSmithKline, Sanofi Aventis and travel grants from AbbVie. SO has received speakers fee from AbbVie, Alfasigma, Amgen, AstraZeneca, BMS, Johnson&Johnson, Lilly, Novartis, and UCB; consultant fees from Amgen, Johnson&Johnson, Mylan, Novartis and UCB and Grants/research support from GSK and Novartis. AS has received speaker fees from AbbVie, Galapagos/Alfasigma, Janssen, Lilly, Pfizer, Takeda and UCB. JC has received speaker fees from Janssen, Pfizer, Idorsia.
: The scoping review is based on previously conducted studies and does not contain any new studies with human participants or animals.
: Not required.
